Halozyme Therapeu…
USUSDHalozyme Therapeutics Inc (US:HALO) — Biotechnology: Biological Products (No Diagnostic Substances). Количество бирж, на которых торгуются акции компании: 3. На этой странице — цена и график, дивиденды, крупнейшие держатели и история количества акций.
О компании
- Сайт
- halozyme.com
- Сектор
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Штаб-квартира
- San Diego, United States
- Генеральный директор
- Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
- Сотрудники
- 423
- Основана
- 1998
- Акций в обращении
- 113.5 млн на 2026-07-31
- Свободное обращение
- 112.19 млн
- Рыночная капитализация
- 12.53 млрд USD
- Инсайдеры
- 1.11%
- Институциональные инвесторы
- 112.22%
- Отрасль (SIC)
- Biological Products, (No Diagnostic Substances)
- Правовая форма
- XTIQ
- ISIN
- US40637H1095
- LEI
- 529900242I3SV9AGM753
Описание
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Дивиденды
Выплаты дивидендов не обнаружены (проверено 09.10.2026). Компания, вероятно, не выплачивает дивиденды.
Новости этой недели
Новостей с сайта компании пока нет.
Крупнейшие держатели
| Держатель | Доля | Акции | Дата отчета |
|---|---|---|---|
| Blackrock Inc. | 11.69% | 13.27 млн | 2026-06-30 |
| Vanguard Capital Managem… | 4.71% | 5.35 млн | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.67% | 5.3 млн | 2026-06-30 |
| State Street Corporation | 4.56% | 5.18 млн | 2026-06-30 |
| iShares Trust-iShares Co… | 3.66% | 4.15 млн | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 3.32% | 3.76 млн | 2026-06-30 |
| Invesco Ltd. | 2.8% | 3.18 млн | 2026-06-30 |
| Morgan Stanley | 2.5% | 2.83 млн | 2026-06-30 |
| Boston Partners | 2.44% | 2.77 млн | 2026-06-30 |
| Bank of America Corporat… | 2.41% | 2.74 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.4% | 2.72 млн | 2026-06-30 |
| Geode Capital Management… | 2.22% | 2.52 млн | 2026-06-30 |
| William Blair Investment… | 2.21% | 2.51 млн | 2026-06-30 |
| John Hancock Funds III-D… | 1.5% | 1.7 млн | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 1.38% | 1.57 млн | 2026-06-30 |
| SPDR SERIES TRUST-State… | 1.31% | 1.49 млн | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 1.2% | 1.36 млн | 2026-06-30 |
| AIM Counselor Series TRT… | 1.1% | 1.25 млн | 2026-05-31 |
| First TRT Exch-Trd Fd.-F… | 1.05% | 1.19 млн | 2026-08-31 |
| Capitol Series Trust-Ful… | 0.85% | 968 755 | 2026-06-30 |
| TORLEY HELEN I (Chief Ex… | ≈0.68% | 767 780 | 2026-09-11 |
| MATSUI CONNIE L (Directo… | ≈0.16% | 183 035 | 2024-11-29 |
| LABARRE MICHAEL J. (Chie… | ≈0.15% | 173 756 | 2025-02-27 |
| POSARD MATTHEW L (Direct… | ≈0.05% | 58 839 | 2026-09-16 |
| SNYDER MARK HOWARD (Offi… | ≈0.04% | 49 929 | 2026-06-12 |
| CONNAUGHTON BERNADETTE M… | ≈0.04% | 40 418 | 2026-08-10 |
| LABROSSE NICOLE (Chief F… | ≈0.03% | 38 494 | 2026-02-23 |
| HENDERSON JEFFREY WILLIA… | ≈0.03% | 36 572 | 2026-05-05 |
| MIYASHITA AKIKO MONI (Di… | ≈0.02% | 24 937 | 2025-05-01 |
| DUNCAN BARBARA GAYLE (Di… | ≈0.02% | 23 715 | 2026-05-05 |
